Wellington Management Group LLP Raises Holdings in Immunome, Inc. (NASDAQ:IMNM)

Wellington Management Group LLP boosted its position in Immunome, Inc. (NASDAQ:IMNM) by 137.1% in the 3rd quarter, Holdings Channel reports. The firm owned 140,690 shares of the company’s stock after acquiring an additional 81,354 shares during the quarter. Wellington Management Group LLP’s holdings in Immunome were worth $2,057,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after buying an additional 13,757 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Marshall Wace LLP lifted its stake in Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Finally, Sofinnova Investments Inc. grew its position in shares of Immunome by 10.3% in the second quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock valued at $7,934,000 after purchasing an additional 61,284 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Down 7.6 %

NASDAQ:IMNM opened at $11.11 on Thursday. The company has a market capitalization of $693.45 million, a P/E ratio of -1.37 and a beta of 1.83. Immunome, Inc. has a 52 week low of $7.76 and a 52 week high of $30.96. The stock’s fifty day moving average is $12.18 and its two-hundred day moving average is $13.39.

Analyst Upgrades and Downgrades

IMNM has been the topic of a number of analyst reports. Piper Sandler reduced their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Finally, Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has a consensus rating of “Buy” and a consensus target price of $28.83.

Insider Activity at Immunome

In related news, insider Robert Lechleider bought 15,805 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the acquisition, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CTO Philip Tsai purchased 21,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the purchase, the chief technology officer now directly owns 21,000 shares of the company’s stock, valued at $198,030. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 102,862 shares of company stock worth $978,045. Company insiders own 8.60% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.